Literature DB >> 10738871

Subtrochanteric corrective osteotomy for the endoprosthetic treatment of high hip dislocation. Treatment and mid-term results with a cementless straight stem.

C Perka1, R Thomas, H Zippel.   

Abstract

Total hip arthroplasty is problematical in the case of high dislocation. To reposition the hip, a femoral shortening osteotomy is necessary in order to prevent damage to the neurovascular structures. This paper describes the implantation of a cementless straight stem in 15 patients using a simple technique with a simultaneous, derotating and shortening osteotomy. Femur fractures, pseudoarthroses, stem loosening, paresis and deep infections were not found. One socket loosening was revised. Fourteen patients had good or very good results in the Merle d'Aubigne score after a median of 4.3 (range 2-5.6) years of follow-up. The surgical technique described enables the initial stable fixation of a standard prosthesis without additional osteosynthesis. Additional advantages include a shorter duration of surgery, a lower complication rate and a more rapid consolidation of the osteotomy.

Entities:  

Mesh:

Year:  2000        PMID: 10738871     DOI: 10.1007/pl00013762

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  3 in total

1.  [Shortening osteotomy for alloarthoplastic joint replacement for hip dislocation in adults].

Authors:  S W Tohtz; C Perka
Journal:  Oper Orthop Traumatol       Date:  2012-04       Impact factor: 1.154

Review 2.  [Hip arthroplasty in the presence of proximal femoral deformity].

Authors:  A Rakow; P Simon; C Perka
Journal:  Orthopade       Date:  2015-07       Impact factor: 1.087

3.  Cementless total hip arthroplasty in patients with severely dysplastic hips and a previous Schanz osteotomy of the femur: techniques, pitfalls, and long-term outcome.

Authors:  Antti Eskelinen; Ville Remes; Pekka Ylinen; Ilkka Helenius; Kaj Tallroth; Timo Paavilainen
Journal:  Acta Orthop       Date:  2009-06       Impact factor: 3.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.